9-ING-41 in Pediatric Patients With Refractory Malignancies.

Conditions:   Refractory Cancer;   Refractory Neoplasm;   Cancer Pediatric;   Refractory Tumor;   Pediatric Cancer;   Pediatric Brain Tumor;   Neuroblastoma;   Neuroblastoma Recurrent;   Pediatric Lymphoma;   Pediatric Meningioma Interventions:   Drug: 9-ING-41;   Drug: Irinotecan Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials